Supernus Pharmaceuticals, Inc. (FRA:S49)

Germany flag Germany · Delayed Price · Currency is EUR
38.60
+0.40 (1.05%)
Last updated: Dec 5, 2025, 8:02 AM CET
9.04%
Market Cap 2.25B
Revenue (ttm) 580.88M
Net Income (ttm) -16.29M
Shares Out n/a
EPS (ttm) -0.29
PE Ratio n/a
Forward PE 17.68
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 6
Open 38.60
Previous Close 38.20
Day's Range 38.60 - 38.60
52-Week Range 26.20 - 49.00
Beta n/a
RSI 39.75
Earnings Date Feb 25, 2026

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN... [Read more]

Industry Pharmaceutical Preparations
Founded 2005
Employees 674
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol S49
Full Company Profile

Financial Performance

In 2024, Supernus Pharmaceuticals's revenue was $661.82 million, an increase of 8.94% compared to the previous year's $607.52 million. Earnings were $73.87 million, an increase of 5512.84%.

Financial numbers in USD Financial Statements

News

There is no news available yet.